(Q46578436)

23 December 2017

title

Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure (English)

1 reference

23 December 2017

1 reference

Dickstein K

1

1 reference

23 December 2017

Timmermans P

series ordinal

2

1 reference

23 December 2017

Segal R

series ordinal

3

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 November 1998

1 reference

23 December 2017

Expert Opinion on Investigational Drugs

published in

1 reference

23 December 2017

volume

7

1 reference

23 December 2017

issue

11

1 reference

23 December 2017

page(s)

1897-1914

1 reference

23 December 2017

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

The management of chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Preliminary biochemical characterization of two angiotensin II receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Identification of angiotensin II receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Non-peptide angiotensin receptor antagonists bind to tachykinin NK3 receptors of rat and guinea pig brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

DuP 753 is a specific antagonist for the angiotensin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Pharmacology of Nonpeptide Angiotensin II Receptor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Access of peripherally administered DuP 753 to rat brain angiotensin II receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Functional roles of brain AT1 and AT2 receptors in the central angiotensin II pressor response in conscious young spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Beta 2-adrenergic receptor and angiotensin II receptor modulation of sympathetic neurotransmission in human atria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Control of growth in neonatal pig hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Blockade of the pre- and postjunctional effects of angiotensin in vivo with a non-peptide angiotensin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Hormonal modulation of proteinuria in the nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

The continuing unethical use of placebo controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

Bradykinin-mediated effects of ACE inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.11.1897

10.1517/13543784.7.11.1897

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017